progressive supranuclear palsy
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
Alzheimer’s groups call for urgent global focus on women’s brain health
New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Lilly and UNICEF collaborate to improve non-communicable disease prevention
Six-year initiative to improve NCD prevention and care for children in low- and middle-income countries
Lilly commits additional $4.5bn for US manufacturing sites
The company has also opened its first dedicated genetic medicine facility in Indiana in the US
Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn
The acquisition will help Lilly to expand its capabilities in cell and gene therapy
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment
The agreement covers the development of new lead tau morphomer candidates
Lilly to acquire Centessa in deal worth up to $7.8bn
The companies aim to advance treatments for narcolepsy and other sleep-wake disorders